A combination drug treatment that includes Pfizer’s Braftovi has doubled survival time for some patients with advanced colorectal cancer, according to recently released late-stage trial data.
The treatment combines standard chemotherapy, an antibody drug called cetuximab and Pfizer’s Braftovi, a targeted therapy that addresses a cancer mutation called BRAF V600E. “When we bring this together with standard of care chemotherapy, we get really substantially prolonged survival for these patients that are really unprecedented for this disease type,” said Dr. Scott Kopetz, a professor of gastrointestinal medical oncology at the MD Anderson Cancer Center in Texas and a co-principal investigator in the trial.
The results reinforce Pfizer’s position at the forefront of oncology and its drive to redefine outcomes for patients with hard-to-treat cancers.